Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corporation outlines how it is building a biomarker and spatial biology platform spanning research to diagnostics. The company now has over 2,500 instruments installed and more than 6,200 scientific publications citing its Simoa and Spatial Biology technologies in neurology, oncology, immunology, and inflammation.
In 2025 Quanterix acquired Akoya Biosciences, adding high-plex tissue imaging, and Emission, Inc., securing bead manufacturing and a mid-plex platform. It is pushing into Alzheimer’s diagnostics with its LucentAD Complete multi-marker blood test, which received a $897 Medicare reimbursement rate, and a multi-analyte blood test that has FDA Breakthrough Device Designation and a submitted 510(k) for detecting amyloid pathology.
The report also highlights governance and leadership changes, including new directors, a new CEO, and a cooperation agreement with Kent Lake Partners, as Quanterix positions its technology and CLIA-certified laboratory services for broader diagnostic use.
Quanterix reported fourth quarter and full-year 2025 results and issued its 2026 outlook. Q4 2025 revenue was $43.9 million, up from $35.2 million, while full-year revenue was $138.9 million versus $137.4 million in 2024. GAAP gross margin fell to 46.8% for 2025 from 60.5%, and the company recorded a net loss of $107.2 million, wider than $38.5 million a year earlier. Adjusted EBITDA loss was $44.9 million.
Quanterix ended 2025 with $121.6 million in cash, cash equivalents, marketable securities and restricted cash and has implemented $74 million of an $85 million cost-synergy target tied to the Akoya acquisition. The company submitted a 510(k) to the FDA for its multi-analyte Alzheimer’s blood test and CMS set a $897 reimbursement rate for the LucentAD Complete test. For 2026, Quanterix guides to revenue of $169–$174 million, GAAP gross margin of 45–49%, adjusted gross margin of 49–53%, and expects to reach cash flow breakeven in the second half of 2026 and exit the year with about $100 million in cash and no debt.
Quanterix Corp’s chief financial officer, Vandana Sriram, reported equity award and related tax transactions. The CFO received grants of 74,905 performance stock units and 74,905 restricted stock units at a stated price of $0 per unit. Footnotes explain that PSUs vest based on performance conditions and then in four equal annual installments starting on the first anniversary of the grant date, while the new RSU award also vests in four equal annual installments.
The filing also shows exercises of previously granted restricted stock units into common stock, along with share dispositions to cover tax obligations. Specifically, 514 and 263 RSUs were converted into common stock, and 179 and 92 common shares were withheld at $5.74 per share to satisfy tax liabilities. After these transactions, the CFO directly held 26,240 shares of Quanterix common stock.
Quanterix Corp. received an amended Schedule 13G/A showing that a group of affiliated Ameriprise entities collectively report beneficial ownership of 4,996,073 shares of Quanterix common stock, representing 10.7% of the class as of 12/31/2025.
The filing lists Ameriprise Financial, Inc. and multiple UK- and Luxembourg-based subsidiaries with shared voting and dispositive power over these shares. The Ameriprise entities state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Quanterix.
Quanterix Corporation’s Chief Financial Officer, Sriram Vandana, reported a routine tax-related share withholding. On February 4, 2026, 4,395 shares of common stock were withheld by Quanterix to cover tax obligations from the vesting of 12,678 restricted stock units (RSUs).
After this transaction, the CFO beneficially owned 81,618 shares of Quanterix common stock, which includes 55,884 RSUs. This filing reflects a non-open-market transaction coded "F," indicating shares retained for taxes rather than a discretionary sale into the market.
Quanterix CorpEverett CunninghamJanuary 19, 2026813,750 performance-based restricted stock units (RSUs)1,070,000 time-based RSUs
The performance-based RSUs vest only if the volume-weighted average price of Quanterix stock meets specified thresholds within a four-year period, as outlined in his January 8, 2026 employment agreement. The time-based RSUs vest in four equal annual installments on January 19, 2027, 2028, 2029, and 20301,883,750 derivative securities$0
Quanterix Corp filed an initial ownership report for Everett Cunningham, who serves as President, CEO, and a director of the company. This Form 3 indicates that, as of the event date of 01/19/2026, he reports no securities beneficially owned in Quanterix. Both the non-derivative and derivative security tables show no holdings, and the remarks section explicitly states that no securities are beneficially owned.
Quanterix Corporation’s Chief Financial Officer, Sriram Vandana, reported an automatic share withholding related to equity compensation. On 01/15/2026, 274 shares of Quanterix common stock were withheld by the company at a price of $7.95 per share solely to cover tax obligations upon the vesting of 777 restricted stock units (RSUs).
Following this tax withholding, Vandana beneficially owned 86,013 shares of Quanterix common stock, which includes 68,562 RSUs. The company’s year-end reconciliation identified a variance of 310 shares, and the corrected balance is reflected in the reported holdings.
Quanterix Corp President & CEO Masoud Toloue reported a routine tax-related share withholding in company stock. On 01/15/2026, 1,817 shares of Quanterix common stock were withheld by the company at a price of $7.95 per share to cover tax obligations arising from the vesting of 3,722 restricted stock units (RSUs). After this transaction, Toloue beneficially owned 507,310 shares of common stock, which the filing notes include 206,398 RSUs. A year-end reconciliation by Quanterix identified a variance of 681 shares, and the corrected ownership balance is reflected in this filing.
Quanterix Corp director Paul M. Meister reported a stock-based board fee grant. On 01/02/2026, he acquired 3,974 shares of Quanterix common stock at a stated price of $0.00 per share as stock granted in lieu of cash fees for service on the company's Board of Directors and its committees for the third and fourth quarter of 2025. After this grant, he beneficially owned 313,253 shares of Quanterix common stock held directly.